"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...

Treatment with aficamten improved exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy when compared with placebo. Treatment with aficamten improved exercise capacity ...

Hypertrophic cardiomyopathy (HCM) is a primary disease of cardiac muscle characterized by a thickening of the left ventricular wall and often predominantly affecting the interventricular septum. This ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common genetic heart disease, with prevalence estimates from one in 200 ...